The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

First Steps warns moviegoers to silence their cell phones, and sees H.E.R.B.I.E. speak for the first time...which isn't quite ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

Updated clinical data in heavily pre-treated, CAR-T naïve patients with B-NHL shows prolonged duration of response, with ...

PFAS are found in multiple everyday products, such as cosmetics, outdoor clothing and coated pans. This is because of their ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

Cash, cash equivalents, and marketable securities: Caribou had $212.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025, compared to $249.4 million as of December 31, ...

The South Carolina General Assembly has wrapped up its regular 2025 session with accomplishments like bills to reduce ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...